Thursday, May 22 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Thursday, May 22 9:30–11:45am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Wednesday, May 21 8:30–9:30am
Brain Check: Promoting Brain Health and Detecting Cognitive Impairment
Wednesday, May 21 4:30–6pm
Taking the Dialogue to the Next Level: Facilitating Open Communication About Obesity
Thursday, May 22 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Thursday, May 22 9:30–11:45am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Wednesday, May 21 3:30–4:15pm
Skin Deep: Tackling Everyday Dermatologic Cases in Primary Care
Thursday, May 22 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Thursday, May 22 9:30–11:45am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Thursday, May 22 7:30–9:15am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 1)
Thursday, May 22 9:30–11:45am
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 (Part 2)
Wednesday, May 21 8:30–9:30am
Brain Check: Promoting Brain Health and Detecting Cognitive Impairment
Wednesday, May 21 7:30–8:30am
Wednesday, May 21 10:30–11:30am
Keeping Up with the Guidelines: Notable Updates for Primary Care Clinicians
Wednesday, May 21 4:30–6pm
Taking the Dialogue to the Next Level: Facilitating Open Communication About Obesity
Wednesday, May 21 2:45–3:30pm
Breakthroughs in Psychiatry: Emerging Treatments for Common Disorders
Thursday, May 22 12:15–1:15pm
Cardiology in Focus: Breaking Down the Latest Guideline Updates
Disclosures
The following financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute. Relevant relationships will be disclosed at the start of each presentation.
Financial Disclosures
- Charles E. Argoff, MD, FABPM
- AbbVie, Researcher; AbbVie, Lilly, Scilex, Lundbeck, Averitas Pharma, Teva, Impel, Kowa Pharmaceuticals, Nevro, Speaker; Collegium, Scilex, Vertex, Xgene Pharma, Tris, PainScripts, Nevro, Consultant; Lundbeck and Teva, Other; Pfizer and Trevana, Stock Holder (publicly traded company)
- Andrew E. Budson, MD
- Eli Lilly and AbbVie, Advisor; Vox Neuro and Bristol Meyers Squibb, Independent Contractor
- Stephanie Faubion, MD, MBA, FACP, NCMP, IF
- No relevant financial relationships disclosed.
- Lisa M. Ferreira, MD, FOMA
- Information to come
- Joshua T. Goldman, MD, MBA
- Information to come
- Aubrey J. Grant, MD, FACC
- No relevant financial relationships disclosed.
- Jennifer Haley, MD
- No relevant financial relationships disclosed.
- Pamela Kushner, MD, FAAFP
- GlaxoSmithKline, Novo Nordisk, AstraZeneca, Lilly, Abbott, Haleon, Bausch/SALIX, Corcept, Boehringer Ingelheim, Advisor; Novo Nordisk, Lilly, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, Abbott, Phathom, Bausch/SALIX, Intuity, Pfizer, and Janssen., Speaker
- Gagan Mahajan, MD
- Information to come
- Bruce D. Nicholson, MD
- Information to come
- Vani Potluri, MD
- No relevant financial relationships disclosed
- Philip Schoenfeld, MD, MSEd, MSc
- Information to come
- Charles Vega, MD, FAAFP
- Boehringer Ingelheim, and Exact Sciences, Consultant
- Shirah Vollmer, MD
- No relevant financial relationships disclosed
- Karol E. Watson, MD, PhD
- Amarin, Consultant; Amgen, Consultant; Boehringer Ingelheim, Consultant; Eli Lilly, Consultant; Novartis, Consultant
Other Disclosures
All other non-faculty contributors involved in the moderating, planning, development, editing and review of the content have disclosed no relevant financial relationships.